13th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY

This annual Alzheimer's Drug Discovery Foundation (ADDF) conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias.



The ADDF’s funded investigators and top level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunities for collaboration and partnering.
+ show speakers and program
8:30 – 8:50


Welcome & Opening Remarks
Howard Fillit, MD, Executive Director, ADDF

8:50 – 9:30


Plenary: Clinical Development of Neuroprotective Peptide, Davunetide
Michael Gold, MD, Allon Therapeutics Inc.

I. Neuroprotection: Aβ, Tau, and Mitochondria Function
Chair: TBD

9:30 – 9:35


Session Overview: TBD

9:35 – 9:55


Orally Active Bioavailable Metal Attenuating Compounds for Alzheimer’s Disease
Peter Kador, PhD, University of Nebraska Medical Center

9:55 – 10:05


Q&A

10:05 – 10:25


Development and Efficacy Evaluation of Novel Immunotherapy for Human Tauopathies
Kun Ping Lu, MD, PhD, Beth Israel Deaconess Medical Center, Harvard University

10:25 – 10:35


Q&A

10:35 – 11:05


BREAK

11:05 – 11:25


Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)Pramipexole Administered to Subjects with Early Alzheimer's Disease
James Bennett, MD, PhD, Virginia Commonwealth University

11:25 – 11:35


Q&A

11:35 – 11:55


Behavioral Efficacy of Anti-Abeta42 Oligomer Small Molecules
Susan Catalano, PhD, Cognition Therapeutics, Inc.

11:55 – 12:05


Q&A

12:05 – 12:25


Clinical Evaluation of MSDC-0160 in Subjects with Mild Alzheimer's Disease
Jerry R. Colca, PhD, Metabolic Solutions Development Company, LLC

12:25 – 12:35


Q&A

12:35 – 1:30


LUNCH AND POSTER SESSION

II. Neuroprotection: Synaptic Plasticity and Cognitive Enhancement
Chair: TBD

1:30 – 1:35


Session Overview: TBD

1:35 – 1:55


Selective GABA a5 Ligands for Cognitive Enhancement in Patients with Mild Cognitive Impairment
Sharon Rosenzweig-Lipson, PhD, AgeneBio Inc.

1:55 – 2:05


Q&A

2:05 – 2:25


Clinical Development of a Novel Activator of Phosphoprotein Phosphatase 2A for Alzheimer’s Disease
Steven P. Braithwaite, PhD, Signum Biosciences, Inc.

2:25 – 2:35


Q&A

2:35 – 2:55


A New Treatment for Cognitive Disorders
Mauro Costa-Mattioli, PhD, Baylor College of Medicine

2:55 – 3:05


Q&A

3:05 – 3:35


BREAK

3:35 – 3:55


In Vivo Characterization of Novel mGlu5 PAMs in Aged Rats
Jerri M. Rook, PhD, Vanderbilt Center of Neuroscience Drug Discovery

3:55 – 4:05


Q&A

4:05 – 4:25


CRF1 Receptors as a Novel Target for Slowing Age-Related Neurodegeneration
John Csernansky, MD, Northwestern University

4:25 – 4:35


Q&A

4:35 – 4:55


Two Novel Compounds for the Treatment of Alzheimer’s Disease
Marguerite Prior, PhD, The Salk Institute

4:55 – 5:05


Q&A

5:05 – 5:10


Closing Remarks
Diana Shineman, PhD, ADDF

5:10 – 7:00


NETWORKING RECEPTION AND POSTER SESSION

Tuesday, September 11th

8:00 – 8:30


Continental Breakfast

8:30 – 9:10


Plenary: Targeting Aging-Related Mechanisms for Alzheimer’s Disease Intervention
TBD

III. ApoE and Vascular Targets
Chair: TBD

9:10 – 9:15


Session Overview – TBD

9:15 – 9:35


Optimizing Drug Like Compounds that Increase ApoE Release from Human Astrocytes to Treat Alzheimer’s Disease
Rick Jack, PhD, Madera BioSciences, Inc.

9:35 – 9:45


Q&A

9:45 – 10:05


Preventing Leukocyte Adhesion and Impaired Cerebral Blood Flow as a Treatment Strategy for Alzheimer’s Disease
Nozomi Nishimura, PhD, Cornell University

10:05 – 10:15


Q&A

10:15 – 10:35


Gene Delivery of Apolipoprotein E2 as a Treatment for Alzheimer’s Disease
Steve Paul, MD, Weill Cornell Medical College

10:35 – 10:45


Q&A

10:45 – 11:10


BREAK

11:10 – 11:30


Targeting ApoE and ApoE Receptor Pathways for Alzheimer’s Disease Therapy
Guojon Bu, PhD, Mayo Clinic

11:30 – 11:40


Q&A

11:40 – 12:00


Development of Peptidomimetic ApoE/Abeta Binding Inhibitors as an Effective and Non-Toxic Therapeutic Approach for AD
Thomas Wisniewski, MD, New York University School of Medicine

12:00 – 12:10


Q&A



12:10 – 12:30


Identification of Small Molecules That Can Prevent Mitochondrial Dysfunction Associated with the Generation of Apolipoprotein E Fragments in Neurons
Robert Mahley, MD, PhD, The J. David Gladstone Institutes

12:30 – 12:40


Q&A

12:40 – 1:25


LUNCH AND POSTER SESSION

IV. Biomarkers to Accelerate Clinical Development
Chair: Howard Fillit, MD, ADDF

1:25 – 1:30


Session Overview: Howard Fillit, MD, ADDF

1:30 – 1:50


Effects of Brain Beta-Amyloid on Postoperative Cognition
Marek Brzezinski, MD, PhD, University of California, San Francisco

1:50 – 2:00


Q&A

2:00 – 2:20


Dynamic Disease-Monitoring Network Biomarkers for Tracking Frontotemporal Dementia
William Seeley, MD, University of California, San Francisco

2:20 – 2:30


Q&A

2:30 – 2:50


Imaging Agents for Diagnosis of Tauopathic Neurodegenerative Diseases
Jeff Kuret, PhD, Ohio State University

2:50 – 3:00


Q&A

3:00 – 3:20


BREAK

3:20 – 3:40


[18F]-THK523, a Novel In Vivo Tau Imaging Agent
Victor L. Villemagne, MD, Austin Health

3:40 – 3:50


Q&A

3:50 – 4:10


High Resolution Quantitative Magnetization Transfer Imaging in Entorhinal Cortex
Ying Wu, MD, NorthShore University Health System Research Institute

4:10 – 4:20


Q&A

4:20 – 4:40


TDP-43 and Tau as Cerebrospinal Fluid Biomarkers to Discriminate Frontotemporal Dementia Subtypes
Marcel M. Verbeek, PhD, Stichting Katholieke Universiteit

4:40 – 4:50


Q&A

4:50 – 5:00


Closing Remarks
Howard Fillit, MD, ADDF

10 Sep - 11 Sep 2012

Jersey City
United States of America
meeting website